Search results
Results from the WOW.Com Content Network
Insite is a supervised drug injection site in the Downtown Eastside (DTES) neighbourhood of Vancouver, British Columbia, Canada [1] The DTES had 4,700 chronic drug users in 2000 and has been considered to be the centre of an "injection drug epidemic". The site provides a supervised and health-focused location for injection drug use, primarily ...
The group's members have been actively involved in lobbying for support of Insite, North America's first safe injection site, located in the Downtown Eastside of Vancouver. [3] Its board of directors consists entirely of current and former drug addicts. [4] It was co-founded by Ann Livingston and Bud Osborn. [2]
Insite, the first legal supervised safe injection site in North America, opened during his tenure. [6] [7] He also led Vancouver's public health response to the 2003 SARS epidemic. [8] After his retirement, he received an honorary degree at the University of British Columbia in 2008. [9]
For premium support please call: 800-290-4726 more ways to reach us
In September 2003, the Vancouver Coastal Health Authority and the Portland Hotel Society opened Insite, North America's first supervised drug injection site, in Downtown Eastside Vancouver, an area of high drug use. s 4(1) and 5(1) of the Controlled Drugs and Substances Act (CDSA) prohibited the possession and trafficking of controlled substances, and so in order to operate, Insite was ...
It was just before 8 p.m. in late June in the Kensington section of Philadelphia when Rosalind Pichardo, founder of the nonprofit Operation Save Our City, rushed to aid a young man in the middle ...
Drug-related 311 complaints to the East Harlem safe injection site’s address have soared to 272 in 2024, up 377% from just 57 in 2020, the year before the facility opened, according to an NYPD ...
Observations before and after the opening of the Vancouver, British Columbia, Canada Insite facility indicated a reduction in public injecting. "Self-reports" of INSITE users and "informal observations" at INSITE, Sydney and some European SISs suggest that SISs "can reduce rates of public self-injection."